DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Triptorelin
OtherFDA approvedRx required

Triptorelin

Also known as: Trelstar · Triptodur · Decapeptyl
Brands: Trelstar · Triptodur · Decapeptyl

Decapeptide GnRH agonist approved for advanced prostate cancer and central precocious puberty.

A
Grade A
Multiple human RCTs
Human studies24
PubMed citations29
Routeintramuscular
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Synthetic GnRH agonist; chronic administration causes GnRH receptor downregulation and gonadal suppression.

Evidence summary

24
Human studies
29
PubMed citations
25
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
intramuscular

Side effects & safety

From the FDA label
Source
abdominal painarthralgiaastheniaback painconstipationdiarrheadizzinessdyspepsiafatigueheadacheinjection site paininsomnianauseapruritusrashvomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for advanced prostate cancer (Trelstar) and central precocious puberty (Triptodur)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT04557059A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational CohortActive Not Recruiting · Phase 3 · Prostatic Neoplasms · n=693NCT02346253A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate CancerActive Not Recruiting · N/A · Prostate Adenocarcinoma · n=146NCT05050084Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)Active Not Recruiting · Phase 3 · Prostate Adenocarcinoma · n=2050NCT04787744Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)Recruiting · Phase 2 · Prostate Cancer · n=464NCT04513717Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)Active Not Recruiting · Phase 3 · Prostate Adenocarcinoma · n=2753NCT04423211Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)Recruiting · Phase 3 · Biochemically Recurrent Prostate Carcinoma · n=804NCT05879926A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)Recruiting · Phase 3 · Breast Cancer · n=3960NCT05377684Noninterventional, Multicentre, Prospective, Cohort Study Assessing the Quality of Life and Hormonal Levels in Premenopausal Patients With Hormone Receptor-positive and HER2-negative Early Breast Cancer in Italy - ROSE StudyActive Not Recruiting · Early-stage Breast Cancer · n=450NCT06734130A Phase IIA Study of Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate CancerActive Not Recruiting · Phase 2 · Metastatic Castration Sensitive Prostate Cancer · n=25NCT03349905A Randomized Trial of Deferred Versus Fresh Embryo Transfers in Infertile Women Undergoing IVF-ICSICompleted · N/A · Infertility, Female · n=237NCT06129539LIBELULA™: An Open-label, Single-arm, Multi-center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants With Central Precocious PubertyActive Not Recruiting · Phase 3 · Central Precocious Puberty · n=56NCT06832774Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP PatientsRecruiting · Phase 2 · Prostate Cancer Metastatic Disease · n=192

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41578923Foreman A, Klein KO et al. · Efficacy and outcomes of 6-month triptorelin formulation in girls treated for central precocious puberty for 24 months and beyond.Journal of pediatric endocrinology & metabolism : JPEM (2026)HumanPMID 38653206Silverman LA, Geffner ME et al. · Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring.Hormone research in paediatrics (2025)HumanPMID 38718766Breidbart E, Breidbart E et al. · Precocious Puberty and GnRH Analogs: Current Treatment Practices and Perspectives among US Pediatric Endocrinologists.Hormone research in paediatrics (2025)HumanPMID 39754976Gravina A, Gargiulo P et al. · Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.ESMO open (2025)HumanPMID 39998154Lao X, Zhao L et al. · Efficacy of Triptorelin Combined with Recombinant Human Growth Hormone (rhGH) on Serum Sex Hormones, Bone Age, and Clinical Outcomes in Girls with Precocious Puberty.British journal of hospital medicine (London, England : 2005) (2025)HumanPMID 39412628Yu X, Cheng X et al. · A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.Advances in therapy (2024)HumanPMID 38469007Moussaoui W, Lahmamssi FZ et al. · Tamoxifen- and Triptorelin-Induced Major Hypertriglyceridemia: A Case Report.Cureus (2024)PMID 39153499Steen EA, Phillips SA · Transient synovitis associated with leuprolide depot (Lupron).Endocrinology, diabetes & metabolism case reports (2024)PMID 38546114Fanelli D, Moroni R et al. · GnRH analogue triptorelin acetate induces ovulation in jennies during oestrus.Reproduction in domestic animals = Zuchthygiene (2024)PMID 37016694Vercellini P, Bandini V et al. · Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?Human reproduction open (2023)HumanPMID 37266535Valenzise M, Nasso C et al. · Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study.Frontiers in pediatrics (2023)HumanPMID 35909557Yuan X, Chen R et al. · Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty.Frontiers in endocrinology (2022)HumanPMID 27398297van den Driessche H, Mattelaer P et al. · Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study.Drugs - real world outcomes (2020)PMID 32059669Wang Q, Luo M et al. · The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.Respiratory research (2020)HumanPMID 29438592Bolton EM, Lynch T · Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.BJU international (2019)HumanPMID 29957076Bertelloni S, Mucaria C et al. · Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.Expert review of clinical pharmacology (2018)HumanPMID 29177573Frampton JE · Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.Drugs (2018)HumanPMID 27191050Brito VN, Spinola-Castro AM et al. · Central precocious puberty: revisiting the diagnosis and therapeutic management.Archives of endocrinology and metabolism (2017)HumanPMID 27246172Merseburger AS, Hupe MC · An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.Advances in therapy (2017)HumanPMID 25990480Fawzy M, Mesbah Y · Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.Archives of gynecology and obstetrics (2016)Human

Showing 20 of 29 papers. View all on PubMed →